Otsuka Holdings Co., Ltd. (4578.T) fair value

ACCE thesis

Otsuka Holdings sells a mix of CNS drugs, including the antipsychotic Rexulti and the aripiprazole franchise co-developed with Lundbeck, alongside its Pharmaceutical Factory and Nutraceuticals segments such as Pocari Sweat and Soyjoy. The defensible edge is a broad, high-margin specialty pharma book, with a 71.8% gross margin and 20.5% operating margin, paired with a consumer and nutrition arm that is far less exposed to drug pricing. Revenue grew 17.4% over the latest period, and the stock trades at 16.4 times trailing earnings but 23.9 times forward, a gap that tells you the market expects earnings to be reset lower before it recovers, so the forward estimates need checking before anyone leans on the headline growth rate. Return on equity of 13.4% is respectable rather than exceptional for a company of this size, which makes the margin structure and the pipeline cadence the things to test. This is a name worth a deeper look to understand why the forward multiple sits so far above the trailing one and whether the Rexulti and oncology launches can carry that growth through the next few years.